Johnson and Johnson Pharmaceuticals' performance in China

Pharmaceutical Network February 13 - Johnson and Johnson is the world's most comprehensive, the widest distribution of health care products manufacturers, health service providersBased on 2015 sales, Johnson and Johnson Pharmaceuticals ranked seventh in 2015 sales, according to Informa Pharma Intelligence's 2016 Global 100 Mandatory Pharmaceutical Companies RankingAccording to Johnson and Johnson's latest fourth-quarter 2016 results, sales revenue from prescription drug business in 2016 was $33.46 billion, up 6.5 percent from 2015In the Johnson and Johnson prescription drug business, the growth rate in the field of immune diseases and cancer treatment reached 15.1% and 23.7%, respectively, driving the growth of the overall prescription drug businessIn addition, Strong Survivor plans to submit applications for 10 new drugs by 2017 to maintain its growth trend in areas such as the nervous system, immune diseases and anti-tumorBut the results also showed that Johnson and Johnson's sales grew by 9.8 per cent in 2016, while sales in international markets grew by only 1.8 per cent, with slower growth in overseas markets, how has Johnson and Johnson performed in the Chinese market in recent years? According to China's key information CMH data show that In 2015, Johnson and Johnson Pharmaceuticals in the five major terminals in China sales scale of 8.79 billion yuan (excluding Xarelto, including Xi'an Yangsen products), the market share of 0.64%, in all domestic and foreignenterprises in theranked 28th, ranked 10th among foreign-funded enterprisesJohnson and Johnson Pharmaceuticals is expected to sell more than 9.8 billion yuan in 2016, up more than 11% year-on-yearand other multinational pharmaceutical companies in the city gradehospitalchannels dominated, Johnson and Johnson in the city grade hospitals and retaildrugstoressales almost evenly equal, mainly due to Xi'an Yangsen's long-term deep-rooted retail pharmacy marketWith the grass-roots first diagnosis, graded diagnosis and treatment and other grass-roots medical reform continue to advance in depth, prescription into the grass-roots hospitals and retail pharmacies, and the county hospital terminal market potential is strong, major foreign enterprises have sunken the channel, johnson and johnson in the county grade hospital market share will be increasedJohnson and Johnson's products in China are mainly focused on neuropharmaceuticals, skin disease strains and respiratory drugs, which is different from its global sales ofof immunediseases and tumor and neurological diseasesSales of nervous system drugs, musculoskeletal systems and anti-tumor and immunomodulators are expected to grow by more than 15% in 2016, with a further increase in the proportion of these categories in their product compositionthe top ten generic names sold by Johnson and Johnson in China in 2015, the antifungal drug Isoconquin, the digestive system drug dopazolone and the nervous system drug Libamine were ranked one, two, and three, but the forecast in 2016 these generic names in the product composition of the proportion of decline, indicating that Johnson and Johnson sales focus is gradually shifting to other productsIn 2016, Johnson and Johnson reportedly submitted several applications for the listing of heavy-weight drugs to china's food and drug regulator, including the diabetes treatment drug SGLT-2 inhibitor Cagler Net tablets, and the new blood tumor drug Ilutinib capsulesIn addition, Johnson and Johnson's new hepatitis C drug Simerriver capsules are also applied for productionAfter two rounds of layoffs late last year and early this year, Johnson and Johnson's over-the-counter division in China will be reduced to about halfIt can be expected that The future of The Market in China will be the main focus and growth point of prescription drug salesThe following will be an analysis of Johnson and Johnson's key varietiesIsoconazole capsules (Spireno)Isoconazole is a synthetic triazole derivative, which has a broad-spectrum antifungal effect and inhibits the synthesis of fungal cell corneasterolsIn the fourth quarter of 2016, Johnson and Johnson reported sales of infected disease drugs at $3.208 billion, down 12.3 percent from a year earlierIn the domestic systemic antifungal market, Spireno capsules in 2015 market share of 8.47 percent, ranked 4th, Spireno injections and oral fluids with 4.91 percent and 0.71 percent of the share of the 6th and 23rdThe share of Spireno capsules has shown a downward trend in recent yearsIn addition to capsules, the share of injections and oral fluids is expected to pick up in 2016Lipitone tablets (Vistom) 　　Lipaione is a selective monoamine antagonist that can improve positive symptoms of schizophrenia, and it causes exercise
dysfunction, and strong straight fainting is less than the classic antipsychotic In 2015, Veston's market share of antipsychotic drugs was about 6.0%, ranking 6th among top10 brands But the variety of generic manufacturers is numerous, and Viston's market share is expected to decline further in 2016 injection siphonsi-like 　　Invlixi monovanda is an inhibitor of tumor necrosis factors, mainly forrhevostomytosis, Crohn's disease, fistula Crohn's disease and hyperthyroidism According to Johnson and Johnson's fourth-quarter 2016 results, global sales in 2016 were $6,966 million, up 6.2 percent from a year earlier and a record high In the domestic anti-rheumatic targeted drug market, in 2015 class grams with 21.38 percent of the market share in the second place, but by the xiumel and domestic recombinant type II tumor necrosis receptor-antibody fusion protein growth, the share decreased compared to 2014 The share is expected to pick up in 2016 as more cities are covered by health insurance Although the share of individual drugs has declined, Johnson and Johnson has already had a wave of heavy-duty new drugs on the way to market Johnson and Johnson's anti-C hepatitis drug Simerivir capsules have been applied for production in China and are expected to be available in 2017 or 2018 Although the drug's global sales decline is evident, it may be possible to halt the decline if it is available in China However, at the same time into the priority review is also the hundred-time beauty-Squibb several new hepatitis C drugs, whether the market can lead remains to be seen Irutini, which uses blood tumors, also filed for listing in China, where its 2016 results show edgy sales of $1,251 million, up 81.6 percent from a year earlier, and FiercePharma expects global sales of the drug to reach $8.29 billion by 2011, perhaps as a new growth point for Johnson and Johnson in the Chinese market